Viewing nowMglirijeng 10 mg (Empagliflozin)
Empagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

MFDS item code 202101971 · Approved 2021.03.03 · Insurance code 663608390
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used to help control blood sugar in adult patients with type 2 diabetes. It can be effective as monotherapy for blood sugar control, but if necessary, it can be combined with other blood sugar-lowering medications such as Metformin to enhance treatment effects. For instance, combination therapy is recommended for patients who have never used diabetes medications before or are insufficiently controlled with monotherapy. Additionally, combination therapy may be necessary for those not controlled with Metformin monotherapy or in combination with other drugs (such as Pioglitazone, Sulfonylureas, DPP-4 inhibitors, etc.). This medication can also be added for patients who are receiving insulin treatment but still have inadequate blood sugar control. Caution is required when using this medication in patients with cardiovascular diseases, and it should be administered under professional guidance. Therefore, this medication is effectively used to improve blood sugar control in patients with type 2 diabetes.
The recommended dose of this medicine is 10 mg once daily, both as monotherapy and as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this medicine is well tolerated and additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions, 3. Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well and whose glomerular filtration rate remains < 60ml/min/1.73m2 [or CrCl < 60 ml/min], adjust or maintain the dose at 10 mg once daily. Discontinue this medicine if the glomerular filtration rate decreases to < 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or patients on dialysis, as efficacy is not expected. Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. Older adults No dose adjustment based on age is necessary. Renal function and the risk of volume depletion should be considered in patients aged 75 years or older. Initiation of this medicine is not recommended in patients aged 85 years or older because clinical experience is limited (see Precautions, 4. General Precautions).
This medication should not be used in certain patients. First, it should not be administered to patients allergic to the active ingredient or components of this medication. Second, it is not suitable for patients with type 1 diabetes or diabetic ketoacidosis. Third, it should not be given to patients with severely impaired kidney function, end-stage renal disease, or those on dialysis. Fourth, it should not be used in patients with genetic lactose intolerance, galactose intolerance, or lactose enzyme deficiency. For patients with some degree of impaired kidney function, this medication should be administered with caution. Especially in patients with a glomerular filtration rate of less than 60 ml/min/1.73m2, it is advisable not to use this medication from the start. Even if the tolerance to this medication is good, the dose should be adjusted or maintained. If the glomerular filtration rate continues to drop below 45 ml/min/1.73m2, this medication should be discontinued. This medication is not expected to be effective in patients with end-stage renal disease or those on dialysis. For patients with heart failure, especially those with mild to moderate (NYHA class I-II) symptoms, caution should be exercised. It is not recommended for severe (NYHA class III-IV) patients due to a lack of clinical trial experience. The risk of hypoglycemia may increase when this medication is used with insulin or sulfonylureas, so the doses of these medications may need to be reduced. Possible adverse reactions that may occur with this medication include hypoglycemia, genital infections (vulvovaginitis, vulvar infections, balanitis, etc.), urinary tract infections, increased urination, skin rash, urticaria, angioedema, decreased fluid volume, increased serum creatinine, etc. Hypoglycemia, in particular, may occur more frequently when used in combination with insulin or sulfonylureas. This medication can potentially cause serious ketoacidosis, so if symptoms such as nausea, vomiting, abdominal pain, fatigue, or shortness of breath appear, you should immediately notify a doctor and undergo a ketone test regardless of blood sugar levels. Elderly patients, especially those over 75 years of age, are at a higher risk of fluid loss, so caution is needed. In situations where fluid loss is a concern, it is advisable to temporarily discontinue this medication. This medication can cause serious infections such as urinary sepsis, pyelonephritis, and necrotizing fasciitis, so if pain or discomfort occurs in the genital or perineal area, consult medical personnel immediately. Additionally, this medication requires caution due to the risk of hypoglycemia when driving or operating machinery. Women who are pregnant or planning to become pregnant are advised not to use this medication, and nursing mothers should discontinue breastfeeding while taking this medication. The safety and efficacy of this medication in children under 18 years of age have not been established. No specific toxicity symptoms have been reported in case of overdose; however, if an overdose is suspected, appropriate treatment should be sought immediately at a medical institution. This medication should be stored out of reach of children, and care should be taken as transferring it to another container may be detrimental to quality.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent air or moisture from entering. It is best to maintain a storage temperature between 1 degree and 30 degrees Celsius.
Pale yellow, biconvex, round film-coated tablet
30 tablets/box [10 tablets/PTP x 3], 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowEmpagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Korea Prime Pharmaceuticals Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Empagliflozin 10mg
Tablet · Prescription medication
Keeps Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.